Skip to content
FLFunding Landscape
Coming Soon·Opens soon·Synced from source July 6, 2026

Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)

National Institutes of Health

View official posting
Posted
Dec 10, 2025
Closes
No deadline published by the funder
Last verified
Jul 6, 2026

Classification and identifiers

Solicitation number
PAR-26-091
Assistance listing (CFDA)
93.394

Amount

Amount not published by the funder

Who can apply

Small businessFor-profitsNonprofitsState governmentsSchool districtsLocal governments

Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations…

About this opportunity

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support the validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. The applicants have the option of submitting either a biphasic UH2/UH3 (Developmental Cooperative Agreement Phase I/Developmental Cooperative Agreement Phase II) application for 5 years or a monophasic standalone UH3 (Developmental Cooperative Agreement Phase II) application for 3 years to support clinical validation of established assays. The UH2 phase of this NOFO will support analytical validation of a...

Related opportunities

Finding similar opportunities...